C. Zhu Et Al. , "Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation," JAMA Neurology , vol.80, no.7, pp.739-748, 2023
Zhu, C. Et Al. 2023. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. JAMA Neurology , vol.80, no.7 , 739-748.
Zhu, C., Kalincik, T., Horakova, D., Zhou, Z., Buzzard, K., Skibina, O., ... Alroughani, R.(2023). Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. JAMA Neurology , vol.80, no.7, 739-748.
Zhu, Chao Et Al. "Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation," JAMA Neurology , vol.80, no.7, 739-748, 2023
Zhu, Chao Et Al. "Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation." JAMA Neurology , vol.80, no.7, pp.739-748, 2023
Zhu, C. Et Al. (2023) . "Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation." JAMA Neurology , vol.80, no.7, pp.739-748.
@article{article, author={Chao Zhu Et Al. }, title={Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation}, journal={JAMA Neurology}, year=2023, pages={739-748} }